Triple-negative breast cancer (TNBC) is characterized by the absence of ER, PR, and HER2 expression, with high invasiveness and strong metastatic potential. Patients with TNBC have a poor 5-year survival rate (77.1%) and show limited response to hormone or HER2-targeted therapy. Currently, chemotherapy remains the main treatment option for TNBC. Therefore, the development of TNBC-specific targeted therapy is urgently needed. To address this need, CCR5 has emerged as a potential therapeutic target. CCR5 is expressed in more than 95% of TNBC tumors, and its overexpression is associated with increased cell migration and poor prognosis. CCR5 promotes the metastatic phenotype of cancer cells, and blocking CCR5 has been reported to reduce cancer cell invasion and metastasis. In this study, we aimed to identify novel compounds with greater anti-metastatic efficacy than the existing CCR5 inhibitor, maraviroc. We evaluated two novel CCR5 inhibitors (PAS-002 and PAS-102) in MDA-MB-436 cells using assays assessing cell viability, migration, invasion, and EMT marker expression. Consequently, both compounds inhibited migration and invasion more strongly than maraviroc without cytotoxicity. The most marked inhibition was observed with PAS-102, a CCR5-selective inhibitor, and was more pronounced in CCR5-overexpressing cells than in vector controls. Taken together, these results suggest that PAS-102 is a promising candidate for suppressing TNBC metastasis, warranting further study.